Advanced NanoTherapies closes Series A funding round
Ngày 02/07/2022 08:26 | Lượt xem: 731

Advanced NanoTherapies has closed a US$7.2 million Series A equity financing round marking a total of US$12.5 million raised since September 2020. Funds will be used to complete the first-in-human clinical study in Australia of the SirPlux Duo drug-coated balloon (DCB) in de novo coronary artery disease (CAD) lesions. Funding comes from sources in the USA, Canada, Europe and Asia.

“Interventional therapies have historically advanced in big steps—angioplasty, bare-metal stenting, drug-eluting stenting,” says Reggie Groves a member of the board of directors at Advanced NanoTherapies. “We believe the interventional cardiology space is poised for the next disruption in the treatment of coronary artery disease with the unique offering of the SirPlux Duo DCB. We are pleased to initiate the next phase of Advanced NanoTherapies’ clinical program.”

“With the advent of cutting-edge drug delivery platforms, it is no longer acceptable to deliver drugs to arterial tissue using a haphazard, undirected approach,” stated Aloke Finn (University of Maryland, College Park, USA). “SirPlux Duo will be the first dual active pharmaceutical ingredient (API) solution to provide a fully targeted, safe, and potent drug delivery option for preventing neointimal growth after coronary and peripheral interventions.”

The SirPlux Duo DCB combines the synergistic power of Sirolimus and Paclitaxel to create a next-generation, front-line therapy engineered to provide stent-like patency and restenosis prevention while leaving no implant behind, Advanced NanoTherapies said in a press release. The company adds that SirPlux Duo DCB delivers low-dose, long-term release of both compounds to inhibit cell growth, resulting in maximum potency exceeding any other DCB or drug-eluting stent. The Advanced NanoTherapies nanoparticle drug-encapsulation and delivery platform provides safe, reliable, and sustained bioavailability of the two synergistic drugs in tissue, it states.

“Sirolimus and paclitaxel are both proven drugs in the vascular space, each with unique benefits, limitations, and mechanisms of action,” commented Mehdi Shishehbor (Case Western Reserve University School of Medicine, Cleveland, Ohio) and chief medical officer of Advanced NanoTherapies. “Pre-clinical data have shown that using both drugs in combination results in higher antiproliferative potency at lower doses than using each drug independently. The synergistic effects of eluting them simultaneously over long periods may be the key to sustaining patency following interventions.”

“We are excited to close this round as we prepare for clinical testing of the SirPlux Duo DCB in de novoCAD patients,” said Marwan Berrada, co-founder and CEO of Advanced NanoTherapies. “Thank you to everyone involved in helping us reach this important milestone. The Series A funding will allow us to gather first-in-human clinical data before the end of 2022, a key step to accelerating the paradigm shift of leaving nothing behind in coronary arteries.”

Source CardiovascularNews

Duc Tin CLinic

Print Chia sẽ qua facebook bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua google bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua twitter bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua MySpace bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua LinkedIn bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua stumbleupon bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua icio bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua digg bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua yahoo bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua yahoo bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua yahoo bài: Advanced NanoTherapies closes Series A funding round Chia sẽ qua yahoo bài: Advanced NanoTherapies closes Series A funding round

Tin tức liên quan

CUSTOMER REVIEWS

  • I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

    I sincerely thank you !. Tel: 0938303275

  • Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

    Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

  • As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

  • The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

  • I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.

Search
Customer support

    Phone: (028) 3981 2678
    Mobile: 0903 839 878 - 0909 384 389

TOP